Document is current
Any future updates will be listed below
-
Authors
Fang, Zhenhao
Peng, Lei
Lucas, Carolina
Lin, Qianqian
Zhou, Liqun
Yang, Luojia
Feng, Yanzhi
Ren, Ping
Renauer, Paul A.
Monteiro, Valter S.
Hahn, Anne M.
Park, Jonathan J. http://orcid.org/0000-0001-5887-3953
Zhou, Xiaoyu
,
Billig, Kendall
Breban, Mallery I.
Castaldi, Christopher
Chaguza, Chrispin
Chen, Nicholas
Ferguson, David
Kerantzas, Nicholas
Koch, Tobias R.
De Kumar, Bony
Landry, Marie L.
Peaper, David
Pham, Kien
Schulz, Wade
Tikhonova, Irina R.
Vogels, Chantal B. F.
Grubaugh, Nathan D.
Wilen, Craig B. http://orcid.org/0000-0003-2495-9403
Chen, Sidi http://orcid.org/0000-0002-3819-5005
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-21-1-0019)
- License Information
-
More Information
Article History
Received: 29 March 2022
Accepted: 9 June 2022
First Online: 19 July 2022
Conflict of interest
: We declare that none of the authors have competing financial or non-financial interests related to this study as defined by Nature Portfolio. S.C. is a Founder of EvolveImmune Tx, Cellinfinity Bio, and Chen Consulting, all unrelated to this study. The remaining authors declare no competing interest.
: The Yale Human Research Protection Program Institutional Review Board determined that the sequencing and generating a virus isolate from de-identified remnant COVID-19 clinical samples conducted in this study were not research involving human participants (IRB protocol ID 2000028599).
